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Src family tyrosine kinases (SFKs) are involved in a
diverse array of physiological processes, as highlighted in
this review. An overview of how SFKs interact with, and
participate in signaling from, receptor tyrosine kinases
(RTKs) is discussed. And also, how SFKs are activated by
RTKs, and how SFKs, in turn, can activate RTKs, as well
as how SFKs can promote signaling from growth factor
receptors in a number of ways including participation in
signaling pathways required for DNA synthesis, control of
receptor turnover, actin cytoskeleton rearrangements and
motility, and survival are discussed.
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Introduction
In this chapter, we will provide an overview of how Src
family tyrosine kinases (SFKs) interact with, and
participate in signaling from, receptor tyrosine kinases
(RTKs). Much of our understanding of SFK function in
RTK signaling comes from analyses of cells in culture
expressing the three ubiquitously expressed members of
the Src family, Src, Fyn, and Yes. Since the roles of the
individual members of the family have for the most part
not been addressed, and indeed these enzymes may have
redundant functions in the signaling pathways we will be
describing (Roche et al., 1995a, b), we will not
distinguish between them here, but rather use the
generic term SFK. We will ﬁrst give examples of RTKs
that couple to SFKs, and then go on to discuss the many
ways in which SFKs participate in RTK signaling. We
do not intend this review to be comprehensive, rather we
will use selected examples to illustrate SFK signaling, as
well as point out poorly understood or ambiguous areas.
SFKs are downstream of several RTKs
The ﬁrst evidence for the involvement of SFKs in RTK
signaling pathways was the demonstration that Src is
activated by stimulation of quiescent ﬁbroblasts with
platelet-derived growth factor (PDGF) (Ralston and
Bishop, 1985). Subsequent studies have established that
SFKs are involved in signaling from many RTKs,
including PDGF receptor (PDGF-R), epidermal growth
factor receptor (EGF-R), ﬁbroblast growth factor
receptor (FGF-R), insulin-like growth factor-1 receptor
(IGF-1R), hepatocyte growth factor/scatter factor
receptor (HGF-R), colony-stimulating factor-1 receptor
(CSF-1R), stem cell factor receptor (SCF-R), muscle
speciﬁc kinase (MuSK), and others (Belsches et al.,
1997; Parsons and Parsons, 1997; Krystal et al., 1998;
Biscardi et al., 1999b; Abram and Courtneidge, 2000;
Dey et al., 2000; Hong et al., 2004; Mohamed et al.,
2001; Maejima et al., 2003). SFKs can promote
mitogenic signaling from growth factor receptors in a
number of ways, including initiation of signaling path-
ways required for DNA synthesis, control of receptor
turnover (Ware et al., 1997; Wilde et al., 1999), actin
cytoskeleton rearrangements and motility (Chang et al.,
1995; Weernink and Rijksen, 1995), and survival (Karni
et al., 1999).
How are SFKs activated by RTKs? SFKs associate
with PDGF-R (Kypta et al., 1990) via an interaction of
their Src homology (SH)2 domains with Tyr579 of the
activated receptor (Mori et al., 1993). This association is
presumed to initiate SFK activation, by releasing the
intramolecular interaction between the SH2 domain and
the tail, thus allowing the molecule to adopt the
catalytically active conformation. This model is sup-
ported by the observation that a phosphopeptide
modeled on the PDGF-R binding site activates Src in
vitro (Alonso et al., 1995). However, more recent studies
suggest that the activation of SFKs by RTKs may be
more complex than simple recruitment. For example,
the activation of Src by EGF-R in transfected cells
requires the small GTPases Ras and Ral (Goi et al.,
2000). There is also a role for the tyrosine phosphatase
Shp2 in promoting SFK activation in response to
PDGF, EGF, and FGF. Shp2, which is recruited to
activated RTKs, dephosphorylates the Csk-binding
protein PAG, thereby preventing the access of Csk
(the negative regulator of SFKs) to SFKs (Zhang et al.,
2004).
The requirement for SFKs in RTK signal transduc-
tion pathways has been probed primarily in four
different ways, each with its own strengths and
weaknesses. Firstly, RTK-binding sites for SFKs have
been identiﬁed and mutated, and then signaling from the
mutated receptors measured. While this approach can
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unambiguously determine whether stable association of
SFKs with an RTK is required, it does not preclude the
possibility that SFKs participate in RTK signaling
without association. Secondly, interfering mutants of
SFKs have been introduced into cells, usually by
microinjection or transfection. These ‘dominant-nega-
tive’ mutants usually bear a point mutation in the ATP-
binding site that prevents catalysis, although sometimes
a second mutation in the tail tyrosine is introduced, that
has the effect of opening up the conformation of Src. It
is usually considered that these dominant negatives
work by competing with endogenous SFKs for binding
to RTKs. However, it is equally possible that the
dominant negatives compete for downstream effectors,
and it can be hard to determine whether they have the
appropriate speciﬁcity in cells. Thirdly, pharmacological
inhibitors of SFKs have been used. Here care must be
taken that the inhibitor has sufﬁcient selectivity. For
example, the related SFK inhibitors PP1 and PP2 are
potent inhibitors of PDGF-Rs, as well as a number of
other kinases (Blake et al., 2000). Fourthly, ﬁbroblasts
derived from mice lacking the three ubiquitously
expressed SFKs, Src, Fyn, and Yes (SYF cells), have
been a valuable tool (Klinghoffer et al., 1999). But these
cells may not be ideal for mitogenesis studies, since the
presence of the large T antigen (LT) of SV40 in these
cells is thought to over-ride requirements for both SFKs
and Ras (Broome and Courtneidge, 2000; Furstoss
et al., 2002).
In the sections that follow, we will review what is
known about how SFKs participate in RTK signaling.
SFKs promote RTK-initiated DNA synthesis
Whether SFKs are required for mitogenesis in response
to PDGF has been the subject of intense study and
debate. In favor of a role for SFKs in PDGF-induced
mitogenesis are the observations that dominant-negative
forms of SFKs, SFK-neutralizing antibodies, and the
SFK inhibitor SU6656 all inhibit PDGF-stimulated
DNA synthesis (Twamley-Stein et al., 1993; Broome and
Hunter, 1996; Blake et al., 2000). However, other studies
have suggested that SFKs are not required for PDGF-
induced mitogenesis. For example, a mutant PDGF-R
that fails to associate with and activate SFKs can still
induce DNA synthesis (DeMali and Kazlauskas, 1998).
But these studies leave open the possibility that the basal
activity of SFKs is sufﬁcient for proliferation. PDGF-
stimulated mitogenesis is only partially inhibited in SYF
cells (Klinghoffer et al., 1999; Kilkenny et al., 2003),
providing seemingly compelling evidence that SFKs are
dispensable for PDGF-induced mitogenesis. However,
as discussed above, these conclusions are complicated by
the presence of LT in the SYF cells (Broome and
Courtneidge, 2000; Furstoss et al., 2002). A deﬁnitive
answer to this debate will perhaps come when SYF cells
are generated without LT.
SFKs have also been implicated in mitogenesis
induced by members of the EGF family of receptors.
Murine ﬁbroblasts overexpressing Src show an increased
level of EGF-stimulated DNA synthesis (Luttrell et al.,
1988), whereas ﬁbroblasts overexpressing dominant-
negative Src fail to synthesize DNA in response to
EGF (Wilson et al., 1989). Injection of a neutralizing
SFK antibody, as well as overexpression of dominant-
negative SFKs, also inhibits EGF-stimulated DNA
synthesis (Roche et al., 1995b). Taken together, these
data suggest that SFKs are indispensable for EGF-R-
induced mitogenesis in ﬁbroblasts.
The interaction between SFKs and EGF-R may be of
particular relevance clinically, since both kinases are
often overexpressed in breast tumors (Luttrell et al.,
1994; Abram and Courtneidge, 2000). Src has been
found to be tightly associated with overexpressed,
activated EGF-R, probably via the autophosphoryla-
tion site in EGF-R. In addition, murine ﬁbroblasts that
overexpress both Src and EGF-R show not only
increased DNA synthesis but also increased colony
formation in soft-agar, and large tumor formation in
nude mice (Maa et al., 1995). The mechanism for this
synergy between SFKs and EGF-R is not clear, but
it may involve the direct modiﬁcation of EGF-R by
SFKs (Parsons and Parsons, 1997 and see below).
Another clinically relevant member of the EGF receptor
family, Her2, also associates with SFKs in tumor cells
(Muthuswamy et al., 1994; Muthuswamy and Muller,
1995).
In myeloid cells, and in ﬁbroblasts that overexpress
CSF-1R, stimulation by CSF-1 activates SFKs (Court-
neidge et al., 1993), and results in ligand-dependent
association of SFKs with CSF-1R. Autophosphoryla-
tion of CSF-1R at Tyr809 is required for SFK activation
and receptor association, but it appears that the SFK-
binding site is Tyr559 in the juxtamembrane region of the
receptor (Courtneidge et al., 1993; Dey et al., 2000).
CSF-1R-mediated activation of SFKs appears to be
required for mitogenesis. Expression of an SFK-
neutralizing antibody or a dominant-negative Src
mutant blocks CSF-1-induced DNA synthesis in ﬁbro-
blasts engineered to express CSF-1R (Roche et al.,
1995b). Also, CSF-1-stimulated DNA synthesis is
completely inhibited in chicken B cells lacking the
SFK Lyn (Corey et al., 1998).
A role for SFKs in the regulation of FGF-1R
signaling has also been suggested (Klint and Claesson-
Welsh, 1999). Fibroblasts stimulated with FGF-1
showed SFK-dependent tyrosine phosphorylation of
cortactin (Zhan et al., 1993, 1994). Further, the SH2
domain of Src mediates its association with the activated
FGF-1R, and stimulation of ﬁbroblasts with FGF-1
results in enhanced SFK activity (LaVallee et al., 1998).
Another study also reported SFK activation in response
to FGF treatment of some cell types, but not all
(Landgren et al., 1995). SFKs may play a role in
regulating FGF-1-stimulated mitogenesis. One study
showed that mouse embryo ﬁbroblasts (MEFs) obtained
from Src/ mice proliferated normally in response to
FGF-1, suggesting that SFK activity is dispensable for
growth factor-induced mitogenesis (Liu et al., 1999).
However, Src/ MEFs express Fyn and Yes, and these
two SFKs could potentially compensate for the loss of
SFKs and RTKs
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Src (Lowell and Soriano, 1996). Indeed, recent work
demonstrates that SYF cells show an almost complete
block in FGF-1-induced DNA synthesis (Kilkenny et al.,
2003). Further, recovery of FGF-1-induced DNA
synthesis was accomplished by reintroducing Src into
these cells, demonstrating a role for SFKs in FGF-1-
induced mitogenesis in ﬁbroblasts.
Stimulation of IGF-1R in murine 3T3-L1 cells results
in enhanced Src and Fyn kinase activity and increased
DNA synthesis (Boney et al., 2001). The kinase inhibitor
PP1 prevented both the IGF-1-stimulated increase in
DNA synthesis and the tyrosine phosphorylation of Shc
and ERK1/2. Further, overexpression of dominant-
negative Src inhibited the phosphorylation of ERK1/2
in response to IGF-1 stimulation. In sum, these data
suggest that SFKs mediate IGF-1R-induced mitogenesis
via regulation of mitogen-activated protein kinase
(MAPK) signaling. Additional components of this
signaling pathway remain to be identiﬁed.
SCF stimulation of small cell lung carcinoma cells
(H526) results in activation of the SFKs Lck and Yes
(Krystal et al., 1998), concomitant with an interaction of
SFKs with the juxtamembrane domain of SCF-R.
Further, the SCF-induced activation of SFKs may
regulate mitogenesis in H526 cells, since PP1 was shown
to inhibit the SCF-induced increase in cell growth and
DNA synthesis. Further evidence comes from studies
using chimeric CSF-1R mutants that have the ligand-
binding domain of CSF-1R fused to the cytoplasmic
domain of an SCF-R that lacks binding sites for all
signaling pathways except SFKs (Hong et al., 2004). This
chimeric receptor is able to mediate cell proliferation.
Several other RTK families appear to signal through
SFKs, including those of the HGF, NGF, Ret, Eph, and
Axl families. In these cases, less is known about the
mechanism of SFK activation, and how SFKs partici-
pate in signaling from each receptor class. We know that
activation of the HGF receptor Met results in the
association of a number of signaling molecules, including
Src, and there is some evidence that HGF stimulated
mitogenesis may require SFKs (Weidner et al., 1993;
Chen et al., 1998; Maejima et al., 2003). Stimulation of
RTKs of the Axl family, including Axl and Sky, also
results in SFK activation (Toshima et al., 1995; Braunger
et al., 1997). Furthermore, mitogenesis of ﬁbroblasts
stimulated with the Axl ligand Gas6 is inhibited by
dominant-negative Src (Goruppi et al., 1997).
To summarize, SFKs are activated by a number of
RTKs in a variety of cell types. While an absolute
requirement for SFKs may depend on the cell type and
the cellular context under study, the available data
suggest that SFKs promote mitogenesis from a variety
of RTKs.
Loss of p53 releases the SFK requirement for RTK
mitogenesis
In NIH3T3 cells overexpressing LT, neither SFKs nor
Ras are required for mitogenesis in response to PDGF,
apparently because LT expression over-rides mitogenic
control points normally regulated by these signaling
molecules (Broome and Courtneidge, 2000). One me-
chanism by which LT exerts its effects is through
association with, and inactivation of, p53, which
appears to be the key regulatory molecule that is
targeted by SFK signaling. For example, overexpression
of kinase-dead Src or injection of a neutralizing SFK
antibody fails to block PDGF-induced DNA synthesis
in cells overexpressing dominant-negative p53 or in p53
null MEFs (Broome and Courtneidge, 2000; Furstoss
et al., 2002). Further, overexpression of E1B-55K (an
adenovirus protein that inhibits p53 transactivation)
overcomes the block in PDGF-stimulated DNA synth-
esis caused by dominant-negative Src (Furstoss et al.,
2002). Together, these data suggest that one role of
SFKs in PDGF signaling is to oppose the negative
growth effects of p53 (Figure 1).
A pathway between SFKs and Myc
Myc is a transcription factor that is required for
mitogenesis in response to several growth factors
(Bouchard et al., 1998). Its production is controlled on
at least three levels, transcriptionally, post-transcrip-
tionally, and post-translationally. In ﬁbroblasts, early
reports suggested that the basal transcription of the myc
gene was detectable in unstimulated cells, and unaf-
fected by mitogen treatment, rather mitogen stimulation
acted to stabilize myc mRNAs once made (Blanchard
et al., 1985; Dean et al., 1986). We have recently
conﬁrmed that this mechanism operates in NIH3T3 cells
stimulated with PDGF (unpublished observations). The
control of the stability of short-lived mRNAs such as
myc is under intense scrutiny, but how mitogenic signals
impact this control is not yet fully understood (Ross,
1995; Guhaniyogi and Brewer, 2001). Once translated,
Myc protein turnover is also tightly controlled. For
example, it has recently been shown that both MAPK
and phosphatidylinositol 3-kinase (PI 3-K) signaling
pathways act to stabilize the Myc protein via phosphor-
ylation at speciﬁc sites (Sears et al., 1999, 2000).
The observation that the block to PDGF-, EGF-, and
CSF-1-stimulated DNA synthesis caused by dominant-
negative SFKs can be overcome by introducing Myc on
an expression plasmid (Barone and Courtneidge, 1995)
led to the suggestion that SFKs initiate a signal
transduction pathway (probably distinct from the
classical Ras–MAPK pathway), which culminates in
Myc production. The microinjection approach used for
these studies precluded a more detailed analysis of how
SFKs affected Myc production. But the subsequent use
of SU6656, an SFK inhibitor, suggested that it is the
PDGF-stimulated increase in myc mRNA levels that is
in large part under SFK control (Blake et al., 2000).
Exactly how SFKs participate in the production of Myc
is still the subject of active investigation, and some
debate. Additional complexity arises because some
studies have used myc transcription assays, some have
measured mRNA levels, and some have measured
protein levels. We will describe some of these studies
below, pointing out the methods used.
SFKs and RTKs
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A number of possible signaling components have been
identiﬁed using the microinjection assay. For example,
dominant-negative forms of Abl, Shc, and Stat3 all
inhibit DNA synthesis in response to PDGF, and all can
be overcome by enforced expression of Myc, suggesting
that they may lie in an RTK-SFK-Myc pathway
(Blake et al., 2000; Bowman et al., 2001; Furstoss et al.,
2002) (Figure 1). We will discuss each of these proteins
in turn.
In ﬁbroblasts, PDGF and EGF stimulation results in
increased Abl enzymatic activity (Plattner et al., 1999).
The PDGF-stimulated increase in Abl activity is
mediated by SFKs, as it is blocked in SYF cells
and by expression of dominant-negative Src. Abl activa-
tion is required for PDGF-stimulated DNA synthesis
(Furstoss et al., 2002). Overexpression of Myc overcomes
the block in PDGF-stimulated DNA synthesis mediated
by dominant-negative Abl. Furthermore, serum-stimu-
lated increases in myc mRNA levels are reduced in the
presence of an Abl inhibitor (STI571). These data place
Abl downstream of SFKs in the pathway leading to
activation of Myc. However, there may be other
signaling effectors that also participate in this pathway,
since recent data show that the PDGF-mediated activa-
tion of Abl requires activation of both SFKs and
phospholipase Cg (PLCg) (Plattner et al., 2003).
Transcription factors of the Stat family appear to be
central players in SFK signaling downstream of RTKs.
Stats are activated by a variety of peptide mitogens
(Bromberg and Darnell, 2000). Several different studies
have used both pharmacological inhibitors and domi-
nant-negative forms of SFKs, and concluded that SFKs
are required for both PDGF (Blake et al., 2000; Wang
et al., 2000; Bowman et al., 2001; Simon et al., 2002) and
EGF (Olayioye et al., 1999; Kazansky and Rosen, 2001;
Guren et al., 2003; Kloth et al., 2003) stimulation of Stat
tyrosine phosphorylation and activation. The nonrecep-
tor tyrosine kinase Pyk2 is also involved in the SFK-
mediated activation of Stats in response to growth
factors (Shi and Kehrl, 2004), although the mechanism
by which this occurs is not clear. The block to PDGF-
stimulated DNA synthesis induced by a naturally
occurring dominant-negative form of Stat3 (Stat3b)
can be overcome by expressing Myc, potentially placing
Stats in the PDGF-SFK-Myc pathway (Bowman
et al., 2001). Because Stats are transcription factors, the
simplest model would be that Stats increase transcrip-
tion from the myc gene. However, as we have already
pointed out, myc mRNA is constitutively transcribed in
quiescent ﬁbroblasts. A more likely mechanism then is
that Stats control the transcription of other genes that
participate in the stabilization of the myc mRNA.
Figure 1 A model for how SFKs mediate mitogenesis in response to RTK activation. RTK-activated SFKs positively regulate DNA
synthesis via stabilization of myc mRNA and thus increase the production of Myc, a transcription factor required for mitogenesis.
Although perhaps dispensable for stabilization of myc mRNA, RTK-dependent activation of the traditional Ras/MAPK pathway
stabilizes Myc protein in response to growth factor stimulation. The mechanism of SFK-induced mycmRNA stabilization is unknown,
but might involve the activation of a number of effectors including Abl, Shc, Stat3, Vav2, and Rac, as these are required for SFK-
mediated DNA synthesis in response to mitogens (see text, for details). SFKs also stimulate DNA synthesis by opposing the negative
growth effects of p53 and PKCd, although whether either of these effectors is involved in SFK-mediated myc mRNA stabilization is
unknown. Finally, SFK activation results in translocation of RasGRP1 to the Golgi network and activation of Ras signaling there.
Whether Ras signaling within the Golgi participates in mitogenesis is not clear
SFKs and RTKs
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A number of studies have implicated the Ras/MAPK
pathway in the mitogenic stimulation of Myc produc-
tion. For example, CSF-1- and PDGF-induced expres-
sion of Myc protein is inhibited by both the MEK
inhibitor PD98059 and by dominant-negative Ras (Aziz
et al., 1999; Cheng et al., 1999; Sears et al., 1999). In one
case, the level of myc mRNA stimulated by CSF-1 was
also reduced by pretreatment with PD98059 (Cheng
et al., 1999). However, in other studies, the level of
PDGF-stimulated expression of myc mRNA was only
marginally affected by PD98059 (Sears et al., 1999,
2000; Chiariello et al., 2001). Recent work has demon-
strated that the primary role of the Ras/MAPK
signaling pathway is in the stabilization of the Myc
protein in response to mitogenic signaling (Sears et al.,
1999, 2000) (Figure 1). However, there remains the
possibility that there is also a cell type- or context-
dependent requirement for Ras signaling for the
stabilization of myc mRNA. A further understanding
of this important issue will have to await a fuller
description of the mechanism by which mitogens
stabilize mRNAs.
The guanine nucleotide exchange factor Vav2 and the
small GTPase Rac have also been implicated in the
SFK-dependent stimulation of Myc (Chiariello et al.,
2001) (Figure 1). The data suggested a model in which
Vav2 is phosphorylated by SFKs in response to mitogen
stimulation, thus initiating the activation of a Rac-
dependent pathway that controls the expression of the
myc gene. Neither Ras nor MEK was involved in this
pathway. These studies clearly deﬁned that Vav2
phosphorylation in response to PDGF is dependent on
SFKs, in keeping with the fact that Vav2 is required for
v-Src-mediated NIH3T3 transformation (Servitja et al.,
2003). However, caution must be used in assigning roles
for Vav2 and Rac in mitogen stimulation of myc, since
the authors employed myc promoter/reporter assays,
even though the basal level of transcription from the
endogenous myc gene is unaffected by mitogens. It will
be important to determine whether these effectors are
also involved in the regulation of myc mRNA stability
in response to PDGF stimulation, and in what way p53
might ﬁt into this pathway.
The adaptor protein Shc is phosphorylated on
tyrosine in response to many mitogens. Two sites of
tyrosine phosphorylation have been identiﬁed, Tyr317
and Tyr239,240. It has been shown that phosphorylation of
Tyr317 leads to the recruitment of Grb2 and subsequent
activation of the Ras/MAPK pathway (Ravichandran,
2001). The Tyr239,240 site is also a canonical site for Grb2
binding. However, even though overexpression of both
ShcY317F and ShcY239/240F mutants inhibits EGF-stimu-
lated DNA synthesis and cell proliferation, only cells
expressing ShcY317F showed inhibition of EGF-stimu-
lated ERK activation (Gotoh et al., 1997). In contrast,
ShcY239/240F, but not ShcY317F, blocked EGF-stimulated
Myc expression (Gotoh et al., 1997). PDGF stimulation
also results in the phosphorylation of Shc at both Tyr317
and Tyr239,240. Here, SU6656 pretreatment blocked the
phosphorylation of Tyr239,240, but had no effect on the
phosphorylation of Tyr317, suggesting that Tyr239,240 is a
substrate of SFKs, while Tyr317 is probably phosphory-
lated by PDGF-R itself (Blake et al., 2000). In light of
these data, it is more likely that the SFK-dependent
activation of Shc speciﬁcally enhances mitogenesis by
regulating the Myc pathway, and not the Ras/MAPK
pathway. In keeping with this model, expression of a
form of Shc mutated at both Tyr239,240 and the PTB
domain inhibited PDGF-stimulated DNA synthesis,
and Myc but not Fos rescued this block (Blake et al.,
2000). Thus, Shc appears to be another component of
the SFK-Myc pathway (Figure 1). It will be of great
interest to determine what signaling effectors are
recruited to Tyr239,240, and how they are regulated by
SFK activity.
A pathway between SFKs and Ras
The signaling pathway that leads from activated RTKs
to Ras and MAPKs has been described in great detail.
Signaling is initiated by the recruitment of proteins such
as Shc and Shp2 to the activated receptor. These
adaptor proteins in turn recruit the adaptor Grb2 and
its associated protein Sos (a guanine nucleotide ex-
change factor for Ras). Once Ras is activated in this
way, it goes on to activate, in a cascade, the serine/
threonine kinases Raf, Mek, and MAPKs (Medema and
Bos, 1993). However, recent work has suggested that
there is an alternative mechanism that activates Ras
proteins that reside in the Golgi (Figure 1). In this case,
EGF stimulation of cells leads to the Src-dependent
phosphorylation of PLCg, which then causes the
translocation of the Ras guanine nucleotide exchange
factor RasGRP1 to the Golgi where it activates Ras.
The requirement for SFKs for Golgi but not plasma
membrane activation of Ras was demonstrated through
the use of the SFK inhibitors PP2 and SU6656, and by
probing SYF cells (Chiu et al., 2002; Bivona et al.,
2003). It is yet to be determined whether Ras signaling
from the Golgi is required for mitogenesis in response to
peptide ligands. However, it has been shown that the
Golgi form of Ras is required for NGF-stimulated
neurite outgrowth of PC12 cells (Rhodes et al., 1989). In
addition, farnesylation of the CAAX motif in Ras
targets Ras proteins to endoplasmic reticulum (ER) and
Golgi membranes (Choy et al., 1999). It has been shown
that Ras CAAX peptidomimetic, FTI-277, selectively
blocks oncogenic Ras signaling (Lerner et al., 1995),
suggesting that Golgi and ER localization is important
in oncogenic transformation of Ras.
Other SFK mitogenic targets
A member of the protein kinase C (PKC) family, PKCd,
has been implicated in mitogenic SFK signaling down-
stream of RTKs. PKCd is thought to play an inhibitory
role in cell growth (Figure 1). When overexpressed, it
can slow the growth of ﬁbroblasts (Mischak et al., 1993),
and inhibit morphological transformation in a variety of
systems (Li et al., 1996; Perletti et al., 1999). PKCd is
phosphorylated on tyrosine residues in response to
several different stimuli, usually as a result of SFK
SFKs and RTKs
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activity (Li et al., 1994; Denning et al., 1996; Blake et al.,
1999; Kronfeld et al., 2000; Joseloff et al., 2002). SFKs
processively phosphorylate several tyrosines on PKCd
(with Tyr311 being the ﬁrst residue phosphorylated), and
this causes the subsequent degradation of the protein.
Overexpression of a PKCd mutant that cannot be
phosphorylated by SFKs (PKCdY311F) inhibits PDGF-
induced DNA synthesis (Blake et al., 1999). Whether
PKCd is a negative regulator of the Src-Myc or Src-
Ras signaling pathways remains to be established.
SFKs modulate RTKs too
The synergy between SFKs and RTKs is complex and
bidirectional. For example, SFKs have also been shown
to modulate the activity and signaling of RTKs, parti-
cularly EGF-R, PDGF-R, and IGF-R (Thomas and
Brugge, 1997) (Figure 2). Interestingly, this regulation
seems to be most crucial to the function of EGF-R.
We will discuss brieﬂy here the consequences of SFK
phosphorylation of RTKs. We will not discuss in any
detail the physiological contexts in which this SFK
engagement occurs: this will be covered in more detail in
other papers in this issue.
Ligand-induced dimerization of the EGF-R results in
the rapid phosphorylation of various EGF-R tyrosine
residues, including positions 992, 1068, 1086, 1148, and
1173 (Wright et al., 1996; Haskell et al., 2001), and
activation of intrinsic kinase activity. These sites then
further participate in signaling by serving as recruitment
points for various signaling and docking proteins. In
addition to these autophosphorylation sites, however,
SFK activation can lead to additional tyrosine phos-
phorylation of EGF-R and to activation of EGF-
dependent signaling. For example, coexpression of
EGF-R and of a temperature-sensitive mutant of v-Src
in Rat-1 ﬁbroblasts induces rapid tyrosine phosphoryla-
tion of two non-autophosphorylation sites in EGF-R
(Wasilenko et al., 1991). Further studies using puriﬁed
wild-type or kinase-dead EGF-R and c-Src identiﬁed
three potential sites responsive to c-Src phosphorylation
in vitro: Tyr1148, Tyr1173, and possibly Tyr703 (Wright et al.,
1996). Tyr703 but not Tyr1173 is also phosphorylated by
c-Src in vivo, suggesting that the conformation of the
receptor may be crucial in determining its sensitivity to
c-Src activity. Finally, recent work has also shown that
Tyr845 and Tyr1101 are both phosphorylated by c-Src in
vitro and in vivo (Tice et al., 1999; Biscardi et al., 2000).
Tyr845 is particularly noteworthy, since in other RTKs
(including CSF-1-R, HGF-R, and FGF-R) the equiva-
lent site is an autophosphorylation site. This might
suggest that SFKs play a unique role in the regulation
of EGF-R by phosphorylating this site (Haskell et al.,
Figure 2 A model for how SFKs participate in RTK signaling. Oncogenic forms of SFKs phosphorylate RTKs. SFKs activated by
cellular signaling also phosphorylate RTKs (in the example shown, SFKs are activated by a G-protein-coupled receptor (GPCR)).
Once activated by RTKs, SFKs regulate receptor turnover both at the level of endocytosis and ubiquitination. SFKs also participate in
RTK-stimulated cytoskeletal reorganization, migration, and survival
SFKs and RTKs
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2001). Indeed, it has been shown recently that integrin
engagement induces phosphorylation of EGF-R on a
number of residues including Tyr845 (as well as Tyr1068,
Tyr1086, and Tyr1173) (Moro et al., 2002). Further,
pretreatment of cells with the SFK inhibitor PP1 or
the expression of dominant-negative Src blocks this
integrin-mediated phosphorylation of EGF-R. These
data suggest that, in response to cell adhesion, c-Src is
recruited to an integrin-containing complex, where it
then phosphorylates EGF-R at Tyr845.
What is the functional consequence of the direct
phosphorylation of EGF-R by SFKs? In most cases,
Src-dependent phosphorylation of EGF-R can posi-
tively regulate EGF-R signaling and cellular prolifera-
tion, with Tyr845 playing a particularly important role. In
cells transfected with a Y845F mutant version of EGF-
R, EGF-stimulated DNA synthesis is severely impaired
when compared to wild-type EGF-R-transfected cells
(Biscardi et al., 1999a; Tice et al., 1999). Taken together,
these data demonstrate that c-Src-mediated phosphory-
lation of Tyr845 is required for EGF-R signaling and
mitogenesis.
SFKs also regulate PDGF-R by phosphorylating
critical tyrosines. For example, Src phosphorylates
Tyr934 of PDGFb-R in vitro (Hansen et al., 1996). Phos-
phorylation of this site is also observed in ﬁbroblasts
stimulated with PDGF, suggesting that PDGF-R is a
Src substrate in vivo. Fibroblasts expressing a mutant
PDGFb-R with a tyrosine to phenylalanine amino-acid
substitution at position 934 (PDGFb-RY934F) show
reduced levels of PDGF-BB-stimulated DNA synthesis,
in keeping with a role for SFK-dependent phosphory-
lation of Tyr934 in proliferative responses (Hansen et al.,
1996). Interestingly, ﬁbroblasts overexpressing PDGFb-
RY934F show increased chemotaxis and actin remodeling
in response to PDGF stimulation, suggesting a negative
role for Tyr934 in these responses.
SCF-R is closely related to PDGF-bR. Recent work
shows that SFKs can directly and selectively phosphor-
ylate Tyr900 of SCF-R (Lennartsson et al., 2003). This
tyrosine, which is not phosphorylated by the intrinsic
kinase activity of SCF-R, serves as a binding site for
CrkII (Lennartsson et al., 2003). Further, cells over-
expressing SCF-RY900F show decreased proliferation in
response to SCF, even though levels of ERK activation
are similar (Lennartsson et al., 2003). Interestingly,
Tyr900 corresponds to Tyr934 in PDGFb-R, suggesting
that these two receptors may share some common SFK-
dependent receptor phosphorylation signaling compo-
nents.
Finally, EGF-R can be transactivated by PDGF-R
(Countaway et al., 1989; Decker and Harris, 1989), and
the signaling activity of PDGF-R can depend on the
coexpression of EGF-R (Li et al., 2000), suggesting a
mutual codependence of these two receptors. PDGF-R-
dependent transactivation of the EGF-R appears to be
SFK-dependent, since PP2 will inhibit it (Saito et al.,
2001). While these results are complicated by the fact
that PP2 is known to inhibit PDGF-R (Blake et al.,
2000), the dose of the inhibitor used may have been
selective for SFKs (Saito et al., 2001).
IGF-1R is also subject to regulation by SFKs
(Thomas and Brugge, 1997). The b subunit of IGF-1R
is constitutively phosphorylated in cells transformed by
v-Src, and the level of IGF-1-stimulated receptor
tyrosine phosphorylation in these cells is much greater
than levels seen with IGF-1R from nontransformed
cells (Kozma and Weber, 1990). Enhanced tyrosine
phosphorylation is observed even in cells expressing
kinase-dead IGF-1R mutants, suggesting that receptor
kinase activity is dispensable (Peterson et al., 1994,
1996). Further, Src-dependent tyrosine phosphory-
lation of IGF-1R increases the levels of phosphorylation
of poly(Glu,Tyr) as well as IRS-1 in vitro, suggesting
that Src-dependent regulation of IGF-1R enhances
its catalytic activity (Peterson et al., 1994). In human
pancreatic carcinoma cells (PANC-1), overexpression
of constitutively active Src increases levels of IGF-1-
induced as well as IGF-1-independent proliferation,
probably in part by enhancing signaling from the
receptor, and also by increasing receptor number
(Flossmann-Kast et al., 1998).
One interesting difference between the SFK regula-
tion of IGF-1R, and the EGF and PDGF receptors is
particularly noteworthy. For both EGF-R and PDGF-
R, the Src-dependent tyrosine phosphorylation sites are
distinct from those sites phosphorylated in response to
growth factor stimulation. In the case of IGF-1R, these
sites are identical both in vitro and in vivo (Peterson et al.,
1996), suggesting that in the case of IGF-1, SFKs
positively regulate the receptor in a manner analogous
to ligand stimulation.
SFKs regulate the turnover of RTKs
Endocytosis
It is well established that many RTKs are endocytosed
after engagement with their ligands. Endocytosis is
primarily thought to be a mechanism for signal
attenuation, although there are also suggestions of
speciﬁc signaling pathways activated by endocytosis
(Marmor and Yarden, 2004).
Many of the studies on RTK endocytosis have been
carried out using EGF-R. Stimulation of cells with EGF
results in rapid clustering of EGF-R complexes in
clathrin-coated pits and their translocation into clathrin-
coated endocytic vesicles (Gorden et al., 1978; Carpen-
tier et al., 1982; Jiang and Sorkin, 2003). Cells over-
expressing Src show an increased rate of EGF-R
internalization (Ware et al., 1997). In addition, inter-
nalization of EGF-R is impaired in SYF cells, and in
cells treated with PP1 (Wilde et al., 1999). The authors
propose that EGF treatment of cells resulted in the
SFK-mediated phosphorylation of clathrin, which
drives its subsequent redistribution to the cell periphery
(Wilde et al., 1999).
Other studies have implicated the SFK-mediated
tyrosine phosphorylation of dynamin in the control
of endocytosis (Ahn et al., 2002) (Figure 2). Dynamin,
a large GTPase, was ﬁrst identiﬁed as a microtubule-
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binding protein (Shpetner and Vallee, 1989). Subsequent
studies revealed that dynamin plays a crucial role in
receptor-mediated endocytosis of EGF-R and transfer-
rin (Kosaka and Ikeda, 1983; Kessell et al., 1989;
Damke et al., 1995). Endocytosis of ligand-induced
RTKs requires dynamin-mediated GTP hydrolysis,
which is regulated by dynamin self-assembly. Phosphory-
lation of dynamin at Tyr597 plays a critical role in its self-
assembly and GTPase activity, and it is phosphory-
lation at this site that is dependent on SFKs (Ahn et al.,
2002). A strong association between Src and dynamin
has also been reported and is mediated by the SH3
domain of Src and the PxxP motif of dynamin
(Okamoto et al., 1997).
Others have failed to ﬁnd a role for SFKs in EGF-R
internalization, and suggested instead that kinases other
than SFKs were involved (Sorkina et al., 2002). The
reconciliation of these differences will clearly require
further study. Nevertheless, a requirement for SFKs has
also been reported for the efﬁcient endocytosis of SCF-
R (Broudy et al., 1999; Jahn et al., 2002), and for
PDGF-Rs, both a and b forms (Mori et al., 1994; Avrov
and Kazlauskas, 2003).
Ubiquitination
The E3 ubiquitin ligase Cbl is a negative regulator of
activated SFKs (Broome et al., 1999; Harris et al., 1999),
and overexpression of Cbl can inhibit Src-driven DNA
synthesis (Broome et al., 1999) and transformation (Kim
et al., 2004). However, under some circumstances, SFKs
can negatively regulate Cbl. For example, Cbl is a
substrate of SFKs, and once phosphorylated, its
conformation is changed (Kassenbrock and Anderson,
2004), and its interaction with the ubiquitin-conjugating
enzyme UbcH7 is destabilized (Yokouchi et al., 2001)
(Figure 2).
The mechanism of Cbl-mediated RTK regulation has
been best characterized for the EGF-R (Dikic, 2003).
EGF-R activation results in recruitment of Cbl to the
EGF-R via association with the autophosphorylation
site Tyr1045 (Levkowitz et al., 1999) and subsequent Cbl-
mediated monoubiquitination of receptor (Joazeiro
et al., 1999; Zheng et al., 2000). Although previous data
suggested that this Cbl-mediated monoubiquitination
stimulated EGF-R endocytosis (Soubeyran et al., 2002;
Jiang et al., 2003), recent studies using Cbl/ MEFs
suggest that Cbl regulates the sorting of EGF-R to
lysosomes (and subsequent degradation there) and not
EGF-R endocytosis per se (Duan et al., 2003). Regard-
less of the exact mechanism, Cbl-mediated EGF-R and
PDGF-R ubiquitination clearly results in the increa-
sed internalization and degradation of both RTKs
(Haglund et al., 2003; Mosesson et al., 2003).
Overexpression of Cbl blocks PDGF- and EGF-
stimulated DNA synthesis in ﬁbroblasts, whereas
introduction of Cbl-neutralizing antibodies potentiates
growth factor-stimulated DNA synthesis (Broome et al.,
1999), suggesting that Cbl plays a negative role in
growth factor-induced mitogenesis. Indeed, the EGF-
stimulated ubiquitination and subsequent proteolysis of
EGF-R are mediated by Cbl (Joazeiro et al., 1999;
Levkowitz et al., 1999; Waterman et al., 1999), and
in some circumstances, SFKs regulate Cbl-mediated
receptor ubiquitination (Kassenbrock et al., 2002; Bao
et al., 2003). Thus, activation of the PDGF-R, EGF-R,
and EphA receptors results in the SFK-dependent
tyrosine phosphorylation of Cbl (Blake et al., 2000;
Rosenkranz et al., 2000; Kassenbrock et al., 2002; Bao
et al., 2003; Sharfe et al., 2003). Inhibition of SFKs not
only blocks the EGF-stimulated phosphorylation of Cbl
in T47D cells and ﬁbroblasts but also inhibits EGF-
stimulated ubiquitination of EGF-R (Kassenbrock et al.,
2002; Bao et al., 2003). Thus, the SFK-mediated
negative regulation of Cbl upregulates levels of EGF-R.
For PDGF-Ra, SFKs seem to enhance Cbl-mediated
degradation of the receptor (Rosenkranz et al., 2000).
Thus, in SYF cells, or in cells expressing a mutant
PDGFa-R that cannot bind SFKs, the half-life of the
receptor is prolonged. Furthermore, overexpression of
Cbl is only able to promote the degradation of receptors
containing SFK-binding sites. How these ﬁndings can be
reconciled with those demonstrating delayed internali-
zation of PDGFa-R receptors (Avrov and Kazlauskas,
2003) is unclear.
SFKs may participate in RTK-initiated cytoskeletal
reorganization, migration, and survival
It is well established that both the introduction of
activated Src into cells and the stimulation of cells with
peptide mitogens such as PDGF lead to rapid and
profound changes in the cytoskeleton. Indeed, studies in
Src-transformed cells have led to the identiﬁcation of a
number of Src substrates with roles in the regulation of
the actin cytoskeleton (Parsons and Parsons, 1997;
Frame et al., 2002). But surprisingly, few studies have
addressed how SFKs activated by, and associated with,
RTKs might be involved in the regulation of actin
dynamics. It is known that PDGF stimulation of ﬁbro-
blasts results in translocation of Src to the cell periphery,
in a process that requires small GTPases and an intact
cytoskeleton (Fincham et al., 1996). Acting through the
tyrosine kinase Abl, SFKs are required for the genera-
tion of membrane rufﬂes in response to PDGF (Plattner
et al., 1999). However, PDGF-induced chemotaxis
occurs normally in SYF cells (Klinghoffer et al., 1999).
Following EGF stimulation of cells, the p190RhoGAP
protein is phosphorylated on tyrosine in an SFK-
dependent fashion (Roof et al., 1998). This phosphor-
ylation acts to relieve an autoinhibitory conformation of
p190, and is required, but not fully sufﬁcient, for p190 to
exert its effects on actin stress ﬁber disassembly. It will be
interesting to determine which other actin regulatory
proteins that are phosphorylated following growth
factor stimulation are substrates for SFKs, and how
phosphorylation by SFKs might affect their function.
Finally, SFKs mediate cytoskeletal anchoring and
stability of acetylcholine receptor clusters in response
to MuSK activation (Mittaud et al., 2001; Mohamed
et al., 2001; Smith et al., 2001).
SFKs and RTKs
PA Bromann et al
7964
Oncogene
Two recently characterized GTPase-binding proteins,
the mouse diaphanous-related formins (mDia)1 and
mDia2, associate with Src and play a role in cytoskeletal
reorganization through Rho GTPases. Activated mDia1
and mDia2 induce signaling downstream of Rho
GTPases along with Src (Tominaga et al., 2000). More
recently, it was shown that mDia-interacting protein
(DIP) is phosphorylated by Src following EGF stimula-
tion (Meng et al., 2004). Phosphorylated DIP in turn
associates with p190RhoGAP and Vav2. As a result,
DIP negatively regulates Rho and positively regulates
Rac, in an SFK-dependent manner.
There have also been reports suggesting the involve-
ment of SFKs in RTK-stimulated migration. For
example, SFK association with SCF-R is required for
migration in response to ligand (Ueda et al., 2002; Hong
et al., 2004), and PP2 inhibits VEGF-induced chemo-
taxis and migration (Abu-Ghazaleh et al., 2001). The
adhesive and motile responses promoted by members of
the family of Eph receptors are also mediated by SFKs
(Bruckner and Klein, 1998; Palmer et al., 2002; Vindis
et al., 2003). But the molecular pathways by which SFKs
promote migration in this context have not been
elucidated.
A similar situation exists for the involvement
of SFKs in RTK-promoted survival (Schlessinger,
2000; Belsches-Jablonski et al., 2001). The use of SFK
inhibitors and receptor mutants has suggested that
SFKs are involved in survival in response to GDNF (a
ligand for Ret) (Melillo et al., 1999; Encinas et al., 2001,
2004), SCF (Hong et al., 2004), and VEGF (Abu-
Ghazaleh et al., 2001), via a mechanism that likely
involves the activation of PI 3-K and Akt. In the case of
EGF-R and Her2, SFKs appear to promote survival via
a Stat-3 dependent increase in Bcl-xL expression (Karni
et al., 1999; Song et al., 2003). Ultraviolet irradiation of
cells can induce ERK activation, which serves as a
survival signal: in this case, ERK activation occurs via
SFK-dependent phosphorylation of EGF-R and sub-
sequent downstream signaling (Kitagawa et al., 2002).
Similarly, cisplatin-induced activation of EGF-R occurs
via SFKs and results in protection (Benhar et al., 2002).
These data suggest that DNA-damaging agents can
generate survival signals that may be dependent on the
regulation of RTKs by SFKs.
In summary, we have learned much in recent years
about how SFKs are regulated by, regulate, and
participate in signaling from, RTKs. In the coming
years, we anticipate that more molecular details will be
added to these pathways. The involvement of SFKs in
RTK signaling may also be exploited clinically, for
example by testing the effects of SFK inhibitors on the
growth, metastasis, and survival of cancers driven by
members of the EGF-R family.
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